search
subscribe by email
Twitter
-
Recent Posts
current comments
topics
- #RunningAtlas (1)
- Adaptive Sports (1)
- Atlas Venture (36)
- Bioentrepreneurship (36)
- Biotech financing (101)
- Biotech investment themes (47)
- Biotech startup advice (65)
- Boards and governance (14)
- Boston Cluster (13)
- Business Development (44)
- Capital efficiency (25)
- Capital markets (48)
- Corporate Culture (52)
- Diagnostics (2)
- Drug discovery (26)
- Exits IPOs M&As (126)
- External R&D (15)
- FDA (3)
- From The Trenches (254)
- Fundraising (15)
- General Venture Capital (46)
- Governance (2)
- Leadership (34)
- Marketing (1)
- New business models (34)
- Patients (11)
- Personal (2)
- Personalized Medicine (4)
- Pharma industry (73)
- Portfolio news (64)
- Pricing and Policy (5)
- R&D Productivity (23)
- Rare Diseases (12)
- Science & Medicine (49)
- Strategy (4)
- Talent (53)
- The Human Element (9)
- Translational research (41)
- Uncategorized (24)
- VC-backed Biotech Returns (67)
monthly archive
- December 2024 (1)
- November 2024 (1)
- October 2024 (2)
- September 2024 (2)
- August 2024 (2)
- July 2024 (3)
- June 2024 (2)
- May 2024 (4)
- April 2024 (4)
- March 2024 (3)
- February 2024 (2)
- January 2024 (4)
- November 2023 (3)
- October 2023 (2)
- September 2023 (1)
- August 2023 (1)
- July 2023 (2)
- June 2023 (1)
- May 2023 (1)
- April 2023 (2)
- March 2023 (3)
- February 2023 (3)
- January 2023 (1)
- December 2022 (2)
- November 2022 (3)
- October 2022 (3)
- September 2022 (1)
- August 2022 (1)
- July 2022 (2)
- June 2022 (4)
- May 2022 (2)
- April 2022 (4)
- March 2022 (7)
- February 2022 (2)
- January 2022 (2)
- November 2021 (5)
- October 2021 (1)
- September 2021 (1)
- August 2021 (2)
- July 2021 (5)
- June 2021 (3)
- May 2021 (3)
- April 2021 (6)
- March 2021 (3)
- January 2021 (2)
- December 2020 (3)
- November 2020 (1)
- October 2020 (6)
- September 2020 (2)
- August 2020 (2)
- July 2020 (3)
- June 2020 (3)
- May 2020 (3)
- April 2020 (6)
- March 2020 (6)
- February 2020 (1)
- January 2020 (1)
- December 2019 (3)
- November 2019 (2)
- October 2019 (2)
- September 2019 (2)
- August 2019 (2)
- July 2019 (1)
- May 2019 (7)
- April 2019 (6)
- March 2019 (1)
- February 2019 (6)
- January 2019 (5)
- December 2018 (1)
- November 2018 (2)
- October 2018 (8)
- September 2018 (4)
- August 2018 (1)
- July 2018 (1)
- June 2018 (4)
- May 2018 (3)
- April 2018 (4)
- March 2018 (4)
- February 2018 (6)
- January 2018 (4)
- December 2017 (3)
- November 2017 (4)
- October 2017 (6)
- September 2017 (4)
- August 2017 (2)
- July 2017 (1)
- June 2017 (5)
- May 2017 (4)
- April 2017 (1)
- March 2017 (5)
- February 2017 (2)
- January 2017 (7)
- December 2016 (3)
- November 2016 (4)
- October 2016 (3)
- September 2016 (6)
- August 2016 (5)
- July 2016 (3)
- June 2016 (6)
- May 2016 (5)
- April 2016 (4)
- March 2016 (7)
- February 2016 (5)
- January 2016 (6)
- December 2015 (6)
- November 2015 (3)
- October 2015 (4)
- September 2015 (5)
- August 2015 (3)
- July 2015 (3)
- June 2015 (4)
- May 2015 (6)
- April 2015 (6)
- March 2015 (7)
- February 2015 (7)
- January 2015 (5)
- December 2014 (4)
- November 2014 (3)
- October 2014 (7)
- September 2014 (5)
- August 2014 (5)
- July 2014 (4)
- June 2014 (6)
- May 2014 (5)
- April 2014 (5)
- March 2014 (6)
- February 2014 (4)
- January 2014 (5)
- December 2013 (3)
- November 2013 (2)
- October 2013 (4)
- September 2013 (3)
- August 2013 (1)
- July 2013 (2)
- June 2013 (2)
- May 2013 (4)
- April 2013 (2)
- March 2013 (4)
- February 2013 (1)
- January 2013 (3)
- December 2012 (3)
- November 2012 (4)
- October 2012 (3)
- September 2012 (4)
- August 2012 (3)
- July 2012 (3)
- June 2012 (4)
- May 2012 (3)
- April 2012 (2)
- March 2012 (3)
- February 2012 (3)
- January 2012 (6)
- December 2011 (4)
- November 2011 (4)
- October 2011 (3)
- September 2011 (4)
- August 2011 (3)
- July 2011 (4)
- June 2011 (4)
- May 2011 (5)
- April 2011 (8)
- March 2011 (10)
Tag Archives: Biotech venture capital
Biotech Venture Ecosystem: Quick Health Check
January 12, 2024
Biotech feels like it’s got some wind in its sails here at the start of 2024, with positive sentiments from the JPM conference. Indeed, the public equity markets feeling somewhat buoyant for the first time in ages. With the close
Value Creation And Destruction: Dispersion of Performance In Biotech IPOs
April 17, 2020
The biotech IPO market in 2020 remains strong, despite the volatility and COVID headwinds. We’ve seen stellar pricings and good after-market performance, with ten new offerings already this year. And the queue for companies with active S1’s on file is
Booming VC-Backed Biopharma: Strong Market Despite Pandemic
April 8, 2020
Venture capital is a long investment cycle business, and never before has that been so clear as now in the face of the ongoing COVID pandemic. Even with the unprecedented public equity market volatility, venture investing into private biopharma companies
The Creation Of Biotech Startups: Evolution Not Revolution
August 15, 2019
The startup paradigm for the creation and funding of new biotech companies has evolved enormously over the past two decades. Recently there’s been a pair of articles from Tech VCs about applying alternative models of company creation (here, here) to
Venture Volatility: 2018’s Banner Year Closed Cautiously
January 16, 2019
2018 was a gangbuster year for VC-funding into startups, reaching levels not seen since the height of the dot-com and genomics era. According to recent data from the NVCA/Pitchbook, VC across all sectors topped $130B invested across nearly 9000 deals
2018’s Biotech IPO Bonanza: View From the After Market
October 17, 2018
2018 has so far been another gangbuster year for biotech IPOs: the first three quarters of the year have delivered nearly 50 new biotech offerings, reinforcing the strong new issuance performance of the past 6 years. With lots of pundits
Another Trophy Quarter For VC-Backed Biotech Funding
April 30, 2018
The flood of capital continues to pour into the private biotech ecosystem, marking the current climate as the most prolific period of investing into the sector of all time. The first three months of 2018 secured yet another “biggest quarter
Of Abundance And Scarcity In Venture Capital
March 13, 2017
As a biotech investor, it’s been fascinating to watch the Snapchat IPO and the fanfare around this $25B sensation following its offering as a “camera” company. As one of the big tech unicorns, it’s justifiably gotten considerable attention in the
VC-Backed Biotech Ecosystem: A Market In Healthy Equilibrium
March 10, 2017
Despite the volatility of biotech stocks in the public markets, the VC-backed private biotech ecosystem has been in remarkable equilibrium for much of the last decade. e·qui·lib·ri·um. noun. a state in which opposing forces or influences are balanced. As I’ve noted
Saluting Biotech M&A: Onward And Upward
September 23, 2016
As larger Pharma externally-enables more of its pipelines, the cadence of biotech M&A appears to be accelerating, especially for early stage deals. Another week, another biotech acquisition in the news: Allergan has acquired two private and two public R&D-stage companies in just
Quantifying The Carnage: Biotech IPO Markets In Turmoil
February 15, 2016
Biotech and the overall equity markets have been under siege the past few months from macro forces, like oil and the economy, as well as sector-specific concerns like drug pricing. After watching the carnage in 2016 wreck havoc with small
Atlas X: Accelerating Biotech Venture Creation
April 17, 2015
Earlier this week Atlas Venture closed Fund X at $280M, completing our transition to a biotech-only venture firm. After announcing the split of our life science and technology franchises in October 2014 (here), we embarked on the hard work of
Venture-Backed Biotech Today: Reflections On Exits, Funding, and Startup Formation
January 22, 2015
Biotech is definitely red-hot, and has been for the past eight quarters. Immuno-oncology, cancer metabolism, gene therapy, orphan diseases, NASH, autoimmune – there’s a broad range of disease settings that are capturing the excitement and imagination of investors today. With some
Early Stage Biotech Venture Scarcity: Fitness, Fear, And Greed
September 22, 2014
The ever-shrinking number of biotech venture capital firms was a common refrain during the 2008-2012 period; it’s true that a large number of firms went under, closed their doors for new investments, or moved into zombie status. I wrote on
Data Insight: The Return Distribution Of BioPharma VC Financings
August 11, 2014
Return distributions in venture capital across different sectors have been a frequent source of commentary, and new data from Correlation Ventures provides further substrate for that theme. I’ve highlighted data from Correlation Ventures (CV) in the past, looking at top
VC-Backed Biotech IPOs: Valuations And Virtuous Cycles
August 4, 2014
As everyone in biotech knows, the last eighteen months have been an unprecedented time in the public capital markets. 2014 is on track to become the best year ever for life science IPOs, topping both 2013 and 2000. Last week
Framing Up Capital Efficiency In Early Stage Biotech
July 17, 2014
Capital efficiency has become a mantra at Atlas, one shared by a number of other early stage biotech investors. It’s a term often repeated in discussions about building young companies, and yet it has become clear that there’s no consistent
Growing Beyond The Startup Phase: Lessons learned
July 1, 2014
So your biotech startup’s graduated to a Series A financing and your investors believe there’s nothing but champagne and robust clinical data in your future. Some classic analogies are applicable here; you’ve found a way off the island, you’ve defeated
Startup Tech Incubator Announces Biotech Experiments
April 28, 2014
Last week Y Combinator, the well-known and very successful technology startup incubator, announced that it was going to begin experimenting with biotech startups. This announcement came as a surprise to many. Several good posts on the subject appeared after a
Pushing Forward With Collaborative R&D Models In Biotech: Roche-Spero And Biogen-Ataxion
April 9, 2014
With today’s announcement of Roche’s deal with Spero Therapeutics LLC (here), and last month’s news regarding Biogen’s deal with Ataxion (here), we’ve added further momentum to our strategy of working closely with larger BioPharma partners to create innovative “external R&D”
Tradeoffs and Timing: IPO vs. M&A Decision Making in Biotech
April 2, 2014
In light of the continued interest in biotech IPOs by the capital markets, there’s probably not a venture-backed biotech boardroom that hasn’t been discussing the merits of going public. Whether warranted or not, taking a company public via an IPO
Unlocking The Promise Of Biotech Startups: Learnings From Mars, Goliath, and Evolution
March 5, 2014
As an early stage biotech investor, the future of the industry and its structure are clearly important things to think about – especially since most of the drug programs our new startups are working on won’t get launched, if they
Immuno-Oncology Startup CoStim Pharmaceuticals Acquired By Novartis
February 18, 2014
Today Novartis announced its acquisition of CoStim Pharmaceuticals, a young biotech company focused on next generation approaches in the exciting immuno-oncology field (here). Their oncology capabilities and commitment to anti-cancer immune mechanisms made them an ideal partner for us at
Biotech IPO Returns: Great, Good, And Not So Good
February 10, 2014
The biotech IPO bonanza appears to be continuing into 2014, with over thirteen offerings already this year. We’re just now completing the busiest two week period in biotech IPOs ever. Another dozen or so companies appear likely to price IPOs
2013’s Untold Biotech Story: Success Of The 2011-12 IPO Class
December 12, 2013
The past year has certainly been the most exciting one for Biotech IPOs since 2000, with dozens of new offerings and compelling therapeutic narratives. But focusing on these new IPOs misses an equal if not more exciting story: the significant
Correlation’s Fresh Look At Venture Capital Returns
November 18, 2013
The broad underperformance of the venture capital asset class during the past decade is widely discussed; there’s a frequently-cited assertion that U.S. venture returns trailed the overall public equity stock market in the 2000s. Few if any published analyses have
Insider Participation Drops As Biotech Offerings Up
October 6, 2013
As you might expect given the strong IPO market, biotech venture investors are doing less of the heavy lifting in support of their portfolio companies during this receptive climate than in the past few years. Biotech insider participation was the
Lessons Learned: Reflections On Early Stage Biotech Venture Investing
February 8, 2013
Venture capital is often called an apprenticeship business in large part because experience matters and takes time to accumulate. But successful firms are able to translate and transfer experiential wisdom through institutional memory, which involves codifying what works and what